

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/856,277
Filing Date	August 20, 2001
First Named Inventor	Peter Josef Leo HESPEL
Group Art Unit	1616
Examiner Name	Sharmila S. Gollamudi
Attorney Docket Number	702-010802

Sheet. 2 of 2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T ²
Not included	7	S. BERMON et al., "Effects of creatine monohydrate ingestion in sedentary and weight-trained older adults"; <i>Acra Physiol Scand</i> 1998, 164, 147-155 - XP-002101316	
Not included	8	JAN HENRIKSSON "Effect of training and nutrition on the development of skeletal muscle"; <i>Journal of Sports Sciences</i> , 1995, 13, S25-S30 - XP-002101315	
Not included	9	HEINANEN ET AL.; "The effect of long-term creatine and guanidinoacetate supplementation on muscle"; University Central Hospital of Turku, and Children's Hospital, Heisinki, Finland XP-002101312 (Abstract)	
Not included	10	SINCLAIR ET AL.; "Creatine supplementation and age influence muscle metabolism during exercise"; <i>J. Appl. Physiol.</i> 85(4): 1849-1856; 1998; XP-002101311	
Not included	11	DA MAHANNA ET AL.; <i>Effects of β-guanidinopropionic acid on murine skeletal muscle</i> "; <i>Experimental Neurology</i> 68, 114-121, pp. 114-121; XP002101313	
Not included	12	WYSS ET AL.; "The therapeutic potential of oral creatine supplementation in muscle disease" 1998, pp. 333-336; XP-002101314	
Not included	13	DERAVE ET AL. "Combined creatine and protein supplementation in conjunction with resistance training promotes muscle GLUT-4 content and glucose tolerance in humans" <i>J. Appl Physiol</i> 94: 1910-1916; 2003	
Not included	14	PETER HESPEL ET AL.; "Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans" <i>Journal of Physiology</i> (2001), 536.2, pp 625-633	

RECEIVED
MAY 12 2003
TECH CENTER 1600/2900

Examiner Signature	Date Considered
	8/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

{W0058333.1}